{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:55:27Z","timestamp":1782212127201,"version":"3.54.5"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>A germline mutation can be identified in up to 10% of patients with primary hyperparathyroidism (PHPT). In 2017, a high frequency of the <jats:italic>GCM2<\/jats:italic> [(NM_ 004752.4) c.1181A&amp;gt; C; p.Tyr394Ser; rs142287570] variant was reported in PHPT Ashkenazi Jews (AJ).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the presence of the <jats:italic>GCM2<\/jats:italic> p.Tyr394Ser variant in Israeli patients addressed for genetic evaluation to characterize their phenotype and clinical management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Patients with PHPT who underwent addressed for genetic screening for suspected familial hypocalciuric hypercalcemia (FHH), a family history of isolated hyperparathyroidism (FIHP), or failed parathyroidectomy with persistent PHPT were recruited. Those with normal initial selected gene sequencing or hyperparathyroid genetic panel completed the <jats:italic>GCM2<\/jats:italic> p.Tyr394Ser variant sequencing. The prevalence of this variant was evaluated using our local genomic database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 42 single individuals from unrelated kindreds were evaluated. A disease-causing mutation was found in 11 (26.1%) patients: 10 were diagnosed with FHH (eight <jats:italic>CASR<\/jats:italic> and two <jats:italic>AP2S1<\/jats:italic> mutations), and one patient had a CKN2B mutation. In 28 of the remaining patients, the <jats:italic>GCM2<\/jats:italic> p.Tyr394Ser variant was positive in three (10.7%), and all were AJ. Within AJ (15\/28, 53.5%), the rate of the p.Tyr394Ser variant was 3\/15 (20%), and of those, two had a history of familial isolated hyperparathyroidism. Multi-glandular parathyroid adenoma\/hyperplasia was also observed in two of these patients. No clinical or laboratory findings could discriminate patients with the <jats:italic>GCM2<\/jats:italic> p.Tyr394Ser variant from those with FHH. Cinacalcet normalized the calcium levels in one patient. The prevalence of the <jats:italic>GCM2<\/jats:italic> p.Tyr394Ser variant in 15,407 tests in our local genomic database was 0.98%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In contrast to previous observations, the <jats:italic>GCM2<\/jats:italic> p.Tyr394Ser variant-associated phenotype may be mild in AJ with FIHP, sometimes mimicking FHH. Because surgery may be curative, surgeons should be aware of the possibility of multiple gland diseases in these patients. The clinical spectrum and clinical utility of screening for this variant warrant further investigation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1254156","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T13:46:21Z","timestamp":1701956781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["GCM2 p.Tyr394Ser variant in Ashkenazi Israeli patients with suspected familial isolated hyperparathyroidism"],"prefix":"10.3389","volume":"14","author":[{"given":"Auryan","family":"Szalat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Shpitzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haggi","family":"Mazeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Durst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vardiella","family":"Meiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101247","DOI":"10.1016\/j.beem.2018.09.013","article-title":"Primary hyperparathyroidism","author":"Silva","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4677","article-title":"International workshop on primary, evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4665","article-title":"Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism","volume":"37","author":"Minisola","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1210\/jc.2018-01225","article-title":"Primary hyperparathyroidism","volume":"103","author":"Bilezikian","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders","volume":"186","author":"Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The american association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism","volume":"151","author":"Wilhelm","year":"2016","journal-title":"JAMA Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01107-5","article-title":"Whole exome sequencing in familial isolated primary hyperparathyroidism","volume":"43","author":"Cetani","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02517","article-title":"Analysis of activating GCM2 sequence variants in sporadic parathyroid adenomas","volume":"104","author":"Riccardi","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab929","article-title":"GCM2 variants in familial and multiglandular primary hyperparathyroidism","volume":"107","author":"Vincze","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kint.2017.08.026","article-title":"Transcription factors that determine parathyroid development power PTH expression","volume":"93","author":"Naveh-Many","year":"2018","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/35018111","article-title":"Genetic ablation of parathyroid glands reveals another source of parathyroid hormone","volume":"406","author":"Gunther","year":"2000","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2018.07.001","article-title":"Causes and pathophysiology of hypoparathyroidism","volume":"32","author":"Cianferotti","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2857","article-title":"Increased prevalence of the GCM2 polymorphism, Y282D, in primary hyperparathyroidism: analysis of three Italian cohorts","volume":"99","author":"D'Agruma","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2016.08.018","article-title":"GCM2-activating mutations in familial isolated hyperparathyroidism","volume":"99","author":"Guan","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1530\/EJE-19-0641","article-title":"Should the GCM2 gene be tested when screening for familial primary hyperparathyroidism","volume":"182","author":"Coppin","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00043","article-title":"Ethnicity of patients with germline GCM2-activating variants and primary hyperparathyroidism","volume":"1","author":"Guan","year":"2017","journal-title":"J Endocr Soc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0370-3","article-title":"Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation","volume":"48","author":"Szalat","year":"2015","journal-title":"Endocrine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2492","article-title":"Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3","volume":"45","author":"Nesbit","year":"2013","journal-title":"Nat Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300253","article-title":"Thakker, Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia","volume":"368","author":"Nesbit","year":"2013","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1241-5","article-title":"Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia","volume":"55","author":"Szalat","year":"2017","journal-title":"Endocrine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4803","article-title":"GNA11 variants identified in patients with hypercalcemia or hypocalcemia","volume":"38","author":"Howles","year":"2023","journal-title":"J Bone Miner Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.04.027","article-title":"Familial isolated primary hyperparathyroidism associated with germline GCM2 mutations is more aggressive and has a lesser rate of biochemical cure","volume":"163","author":"El Lakis","year":"2018","journal-title":"Surgery"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0433","article-title":"Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders","volume":"186","author":"Canaff","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad086","article-title":"Variant Tyr 394Ser in the GCM2 gene is rare in a cohort of ashkenazi jews with primary hyperparathyroidism","volume":"7","author":"Tolkin","year":"2023","journal-title":"J Endocr Soc"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/2022.03.20.48503","article-title":"A genome-wide mutational constraint map quantified from variation in 76,156 human genomes","author":"Chen","year":"2022","journal-title":"bioRxiv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"bvad126","DOI":"10.1210\/jendso\/bvad126","article-title":"A knock-in mouse model of the gcm2 variant p.Y392S develops normal parathyroid glands","volume":"7","author":"Parekh","year":"2023","journal-title":"J Endocr Soc"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1254156\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T13:46:24Z","timestamp":1701956784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1254156\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":27,"alternative-id":["10.3389\/fendo.2023.1254156"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1254156","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"article-number":"1254156"}}